Verily
https://verily.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Verily
‘Stop Fighting Us’ On Inspections, US FDA’s Califf Tells Industry; Foods Modernization Will Bring ‘Big Change’ To Drug Quality Systems
Commissioner Califf underscores need to keep inspections systems ‘tuned up’ to prevent manufacturers from ‘losing their edge’ on quality.
Califf Laments Shift To Ex-US Clinical Trials – As Well As Pace Of Reforms At Home
US FDA commissioner tells J.P. Morgan conference that the agency, industry, and the entire healthcare system need to change ‘at the same time’ in order for clinical trials to improve.
Sosei Heptares Eyes Asia Build-Out On Internal, External Assets
Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.
Financing Quarterly Statistics, Q3 2022
During Q3, biopharmas brought in an aggregate $18.1bn in financing and device company fundraising totaled $5.1bn; while in vitro diagnostic firms and research tools players raised $771m.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Alphabet Inc.
- Verily Life Sciences LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice